Sustained two-year efficacy of lebrikizumab in managing atopic dermatitis symptoms

Summaries 2 min 34

Font Size

Created On: 05/03/2026

Atopic dermatitis is a chronic inflammatory skin disease marked by fluctuating disease activity and persistent pruritus, with interleukin-13 (IL-13) playing a central role in its pathophysiology.

See All

Key take away

Lebrikizumab maintains stable long-term control of skin clearance and itch in patients with atopic dermatitis, with minimal response fluctuations across dosing regimens.

Background

Atopic dermatitis is a chronic inflammatory skin disease marked by fluctuating disease activity and persistent pruritus, with interleukin-13 (IL-13) playing a central role in its pathophysiology. Targeted biologic therapies are increasingly used to achieve durable disease control. Researchers conducted a study on the long-term stability of skin and itch responses over 2 years in patients with atopic dermatitis who initially responded to lebrikizumab treatment.

Method

This analysis included week 16 responders from the phase 3 ADvocate1 and ADvocate2 trials who continued the treatment. Patients received lebrikizumab either every 4 weeks or every 2 weeks. Week 16 response was marked by achieving Investigator’s Global Assessment (IGA) 0/1 with a ≥2-point betterment or attaining at least a 75% decrease in eczema area and severity index (EASI-75) without the need for rescue therapy.

The stability of clinical response was assessed for EASI-90, EASI-75, and pruritus numeric rating scale (NRS) improvements of ≥3 and ≥4 points. Stability was defined as maintaining response during at least 80% of attended visits from weeks 16 to 104, using observed data regardless of rescue medication use or treatment discontinuation.

Result

After 104 weeks of uninterrupted lebrikizumab therapy, the majority of week 16 responders illustrated highly stable skin and itch responses, with minimal fluctuations over time (Table 1).

Conclusion

Continuous lebrikizumab (targeted monoclonal antibody) therapy was associated with sustained and stable improvements in both skin disease severity and pruritus. The consistency of response across multiple efficacy measures supported the durability of IL-13 inhibition as a long-term treatment strategy for chronic disease management.